Japanese maker of OTC pharmaceuticals and niche consumer health products, known for inventive small-category items.
Japanese maker of OTC pharmaceuticals and niche consumer health products, known for inventive small-category items.
Earns by creating a household or health product for a niche no one has served, backing it with heavy advertising, and selling it through drugstores and supermarkets; repeat purchases then carry the brand. Sawaday air fresheners and Netsusama fever-cooling sheets are examples sold on the same shelves as its medicines.
In one line: A niche OTC/consumer-health innovator.
Moat: narrow (brand, IP / patents). Track record of creating and branding new niche product categories ahead of competitors.
Headquarters: Osaka, Japan · Founded: 1886 · Employees: 3,731
Size Kobayashi Pharmaceutical (4967.T) is a Japan Consumer Staples company (Household/Personal Care) with a market value of $3.25B, the 343rd largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥6,960 on 18 Nov 2026.
Performance Over six months the shares gained 19.6%, against +0.3% for the median peer and -1.4% for the Japan market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 2.5% over the last twelve months (peer median +4.3%); the operating margin is 6.1% (peer median 11.5%).
Valuation It trades at 48.7× forward earnings against a peer median of 19.9× (2nd most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +16 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.5 points below its cost of capital (5.0% WACC).
Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥167B | ¥166B | ¥166B | ¥173B | ¥166B |
| Revenue growth | — | 0% | -5% | +4% | — |
| Gross profit | ¥82.7B | ¥79.4B | ¥82.8B | ¥93.2B | ¥89.7B |
| EBITDA | ¥19.8B | ¥23.6B | ¥32.9B | ¥31.8B | ¥31.9B |
| Net income | ¥4.58B | ¥3.66B | ¥10.1B | ¥20.3B | ¥20.0B |
| Free cash flow | n/a | ¥12.3B | -¥14.8B | ¥5.60B | ¥17.2B |
| Capital expenditure | n/a | ¥14.0B | ¥26.6B | ¥13.6B | ¥16.2B |
| Total debt | ¥664M | ¥678M | ¥846M | ¥987M | ¥792M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Kobayashi Pharmaceutical 4967.T | $3.25B | +20% | +2% | 6% | 48.7× | 18.0% |
| Rohto Pharmaceutical 4527.T | $3.87B | +8% | +7% | 12% | 16.5× | -2.8% |
| Earth 4985.T | $687M | +7% | +4% | 4% | 18.0× | -1.6% |
| Lion 4912.T | $3.85B | +44% | +6% | 8% | 24.3× | 0.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4967.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.8% | +2.2% | 8th lowest of 21 |
| 6-month return | +19.6% | +0.3% | 6th highest of 21 |
| Distance from 52-week high | -5.8% | -22.4% | 5th highest of 21 |
| Revenue growth (TTM) | +2.5% | +4.3% | 10th lowest of 21 |
| Operating margin | 6.1% | 11.5% | 5th lowest of 21 |
| Forward P/E | 48.7× | 19.9× | 2nd most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 18.0% | -0.4% | 3rd most demanding of 17 |
| Growth delivered (Del g) | +1.9% | +10.2% | 5th lowest of 17 |
| Hurdle (Req g minus delivered) | +16.1 pp | -3.3 pp | 2nd most demanding of 17 |
| ROIC minus cost of capital | -0.5 pp | +5.3 pp | 4th lowest of 19 |
| EV / EBITDA | 23.4× | 10.3× | 2nd most expensive of 17 |
| Net debt / EBITDA | -2.7× | -0.8× | 5th least indebted of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kobayashi Pharmaceutical 4967.T | Japan | $3.25B | +20% | +2% | 6% | 48.7× | 18.0% | +1.9% |
| Hengan Int'l 1044.HK | Hong Kong | $3.27B | -12% | +2% | 11% | 9.1× | -8.2% | -0.1% |
| Interparfums ITP.PA | France | $3.49B | +66% | -4% | 18% | 26.9× | 15.6% | +19.6% |
| Proya Cosmetics 603605.SS | China | $2.87B | -13% | +2% | 13% | 10.9× | -5.3% | +23.1% |
| Coty COTY | United States | $3.71B | +116% | 0% | 5% | 13.5× | 9.8% | +4.6% |
| LG H&h 051900.KS | South Korea | $2.81B | -14% | -3% | 3% | 23.1× | -4.6% | -4.1% |
| Lion 4912.T | Japan | $3.85B | +44% | +6% | 8% | 24.3× | 0.9% | +3.5% |
| Rohto Pharmaceutical 4527.T | Japan | $3.87B | +8% | +7% | 12% | 16.5× | -2.8% | +13.7% |
| Gillette India GILLETTE.NS | India | $2.53B | -5% | +8% | 28% | 37.1× | 14.9% | +13.0% |
| Winner Medical 300888.SZ | China | $2.53B | -6% | +4% | 11% | 19.9× | -5.2% | -2.6% |
| Cosmax 192820.KS | South Korea | $2.51B | +53% | +25% | 8% | 18.8× | n/a | n/a |
| Giant Biogene 2367.HK | Hong Kong | $2.47B | -32% | -10% | 32% | 8.6× | -10.7% | +34.9% |
| Procter & Gamble Hygiene & Health Care PGHH.NS | India | $2.37B | -30% | -2% | 24% | 27.0× | 21.2% | +7.4% |
| Mao Geping Cosmetics 1318.HK | Hong Kong | $4.67B | -8% | +32% | 31% | 14.3× | 4.1% | +41.1% |
| Softcare 2698.HK | Hong Kong | $2.20B | +5% | +25% | 25% | 14.4× | 9.1% | +20.9% |
| KOSE 4922.T | Japan | $2.16B | +16% | +4% | 5% | 29.9× | n/a | n/a |
| Colgate-Palmolive (India) COLPAL.NS | India | $4.91B | -23% | +9% | 28% | 32.4× | 31.1% | +4.5% |
| Blue Moon 6993.HK | Hong Kong | $2.07B | -4% | -2% | -2% | 103.3× | n/a | n/a |
| Kolmar Korea 161890.KS | South Korea | $2.05B | +14% | +16% | 10% | 14.3× | -1.6% | +15.5% |
| Pola Orbis 4927.T | Japan | $2.04B | +15% | +1% | 11% | 30.6× | -2.0% | -0.7% |
| Cupid CUPID.NS | India | $5.22B | +218% | +125% | 33% | n/a | n/a | n/a |